The present invention relates to pharmaceutical compositions in
particulate form or in solid dosage forms comprising a combination of
fenofibrate and the HMG CoA reductase inhibitor pravastatin or a
pharmaceutically active salt thereof, which upon oral administration
provides a relative AUC.sub.0-24 value (AUC.sub.fibric
acid/AUC.sub.pravastatin) of between about 90 and about 6300. The solid
compositions are manufactured without any need of addition of water or
aqueous medium and comprise at least 80% of the active substances
fenofibrate and pravastatin in dissolved form, or, optionally,
atorvastatin in micronized form, in order to ensure suitable
bioavailability.
